Development and Characterization of the Mode-of-Action of Inhibitory and Agonist Peptides Targeting the Voltage-Gated Sodium Channel SCN1B/β1 Subunit
Treatment of cardiac arrhythmias by targeting ion channels is challenging, with safe and effective therapies remaining an unmet clinical need. Modeling and experimental studies have shown that a voltage-gated sodium channel (VGSC)-rich nanodomain at edge of the gap junction (GJ) called the perinexus could provide new mechanistic insights into normal and abnormal conduction of action potentials in the heart. We have reported that a 19 amino acid SCN1B ({beta}1/{beta}1B) mimetic peptide derived from the immunoglobulin domain of the VGSC subunit called {beta}adp1 acutely disrupts {beta}1-mediated adhesive interactions at cardiac perinexii, prompting arrhythmogenic changes during time courses of up to an hour. In the present study, we sought to gain further insight on {beta}adp1 mode-of-action, as well as identifying new SCN1B ({beta}1/{beta}1B) mimetic peptides, with potential for inhibiting and/or promoting {beta}1-mediated adhesion. This included studies of the effect of {beta}adp1 and related peptides on SCN1B ({beta}1/{beta}1B) Regulated Intramembrane Proteolysis (RIP) - a signaling pathway that has been shown to effect gene transcription, including that of VGSC subunits. Using patch clamp to assay cell-cell contact-associated VGSC activity in cardiomyocytes, and electric cell substrate impedance sensing (ECIS) to assess intercellular adhesion in cells heterologously expressing {beta}1, we find that inhibitory effects of {beta}adp1 can persist for up to 5 hours. However, this acute inhibition is not sustained, with {beta}adp1 effects on {beta}1-mediated adhesion lost after 24 hours. We also determined that a short peptide (LQLEED) near the carboxyl-terminal portion of {beta}adp1 inhibited adhesion in {beta}1-expressing cells in a manner similar to {beta}adp1. Paradoxically, dimeric peptides incorporating a repeat of the LQLEED sequence promoted intercellular adhesion at all time points studied over a 2-day time course. Inhibitory and agonistic peptides were found to effect {beta}1 RIP, with {beta}adp1increasing RIP continuously over 48 hours, whilst dimeric agonists acutely increased RIP at 6 hours post-treatment, but not thereafter. In the presence of DAPT, an inhibitor of RIP, the effects of {beta}adp1 on ECIS-measured intercellular adhesion were lost, suggesting a relationship between RIP and inhibitory effects of the peptide. In sum, we identify novel SCN1B ({beta}1/{beta}1B) mimetic peptides with potential to inhibit and promote intercellular {beta}1-mediated adhesion, possibly including by effects on {beta}1 RIP, suggesting paths to development of anti-arrhythmic drugs targeting the perinexus.